Cortellis Drug Discovery Intelligence
Accelerate drug development with complete discovery and preclinical intelligence
Make confident R&D decisions and avoid late-stage failures
Advance discovery and preclinical development and avoid late-stage failures with drug intelligence that integrates multi-source scientific data into a single drug discovery platform.
Benchmark and improve your drug candidates
Identify and prioritize targets and biomarkers
Increase the success of your preclinical drug discovery programs
Built for scientists, by scientists
Reliable, enriched data
Access timely and accurate preclinical drug discovery content, curated using a combination of technology and human curation by scientists and subject matter experts.
Granular indexing
Search by drug name, disease areas, chemical structure and more, and drill down to the answers you need with 20+ filters and granular indexed data.
Broad and deep coverage
Unmatched breadth of scientific intelligence, covering global sources and spanning 27+ therapy areas and 6500+ diseases, including rare.
Leverage the most comprehensive drug discovery database available
Make informed go/no-go decisions
Tap into critical R&D data to make confident indication prioritization and drug repurposing decisions, and efficiently move drugs through development. Confirm the link between target and indication and connect all related information with a leading drug discovery platform.
Benchmark drugs’ experimental performance
Understand who is developing drugs like yours and compare experimental performance to better assess your competitors. Use previous research to make informed go/no-go decisions regarding your pipeline or design your experiments.
Understand metabolic pathways
Explore active metabolites and uncover desired pharmacological or off-target activity in humans and animal models. Evaluate competitor drug activity in vitro and in vivo and identify the best assays to test the efficacy of your molecules.
Speed up compound synthesis
Conduct structure searches of your compounds to uncover similar compounds and related synthesis schemes, including intermediates. Benchmark drug candidates based on pharmacology and pharmacokinetics to identify competitive strengths and weaknesses.
804k+
47k+
222k
53k+
695k+
1.7m+
Resources
Assessing the potential of PROTACs as treatments for Alzheimer's disease
PROteolysis TArgeting Chimeras (PROTACs) represent a promising class of drugs designed to degrade disease-causing proteins by leveraging the ubiquitin-proteasome system. The PROTAC field is rapidly evolving, with numerous companies and…
Frequently asked questions
Cortellis Drug Discovery Intelligence is trusted by researchers across biopharma and academia, including R&D executives, biologists, pharmacologists, DMPK specialists, medicinal chemists, biomarker and translational scientists.
Cortellis Drug Discovery Intelligence provides you with an integrated source of biological, chemical, and pharmacological data from disparate sources into a single drug discovery platform. Our team of scientific experts select and curate data from the following sources:
- 1500+ scientific journals
- 160+ international conferences
- 7 main patent offices
- Regulatory agencies (FDA, EMA, PMDA & TGA)
- ClinicalTrials.gov
- Pharma & biotech company web pages
Pathway maps are exclusive, curated biological pathways provided in the Cortellis Drug Discovery Intelligence platform. They are graphical representations of molecular and cellular processes that allow you to explore the biological plausibility of the mechanism of action or biomarker of interest by visualizing cellular signaling highlighting key upstream and downstream regulators of a target.
These maps allow you to overlay known drug targets, disease relationships, and adverse events to understand the biological rationale behind a disease or biological process.
Yes, alongside comprehensive insights into animal models used in prior research, this drug discovery platform empowers medicinal chemists and pharmacologists to replace, reduce, and refine the use of animal models for drug testing by confidently assessing organ-on-a-chip and organoid models.
This winning combination provides R&D teams with a holistic approach for optimizing drug discovery and accelerating preclinical testing. By coupling comprehensive biological, chemical and pharmacological data from Cortellis Drug Discovery Intelligence with drug safety data from OFF-X, researchers can anticipate risks and successfully translate drugs from lab to clinic.
Yes, you can leverage bulk data from this drug discovery database as a data feed or API to populate internal data and analytics solutions.
Follow us
Contact us
